ArticleHaematologica2012

A novel combination therapy approach for the treatment of acute myeloid leukemia: the multi-kinase inhibitor sorafenib and the HDM2 inhibitor nutlin-3.

Ellen Weisberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.